Piramal Pharma

Piramal Pharma Limited is the publicly traded pharmaceutical arm of Piramal Group, headquartered in Mumbai, India. It traces its roots to Nicholas Laboratories (founded in 1947) which became Piramal Healthcare Limited after its 1988 acquisition by the Piramal Group.^[4] In 2010, the company’s domestic formulations business was divested to Abbott Laboratories. The remaining business was reorganized and renamed Piramal Pharma Limited in 2022.^[5] Today, Piramal Pharma operates in three segments—Piramal Pharma Solutions (CDMO), Piramal Critical Care (hospital generics), and Consumer Healthcare—serving markets in over 100 countries.^[6] It is listed on the Bombay Stock Exchange and the National Stock Exchange of India.^[7]

Piramal Pharma Limited traces its origins to Nicholas Laboratories, founded in 1947, which was acquired by the Piramal Group in 1988 and later renamed Piramal Healthcare Limited. ^[8] In 2010, the company divested its domestic formulations business—including established OTC brands—to Abbott Laboratories in a deal valued at approximately USD 3.7 billion. ^[9] The remaining business—comprising contract manufacturing, critical care generics, consumer healthcare, and other services—was reorganized and demerged into Piramal Pharma Limited, which was listed as a separate entity in 2022. ^[10]

Piramal Pharma Limited operates through three principal business segments:

• Piramal Pharma Solutions (PPS) – A global Contract Development & Manufacturing Organization (CDMO), offering end-to-end services including formulation development, API/finished dosage manufacturing, peptide products, and sterile fill-finish. It supplies these services across regulated markets in North America, Europe, and Asia. ^[11]
• Piramal Critical Care (PCC) – A top-tier hospital generics provider, especially noted for inhalational anaesthetics (like sevoflurane and isoflurane), intrathecal baclofen, and injectable anesthetics. Its products are distributed in over 100 countries and many of its manufacturing facilities are approved by US FDA and UK MHRA. ^[12]
• Consumer Healthcare – A division focused on OTC products in the Indian market, offering a diverse portfolio including self-care brands like Lacto Calamine, i-Pill, and others. ^[13]